Â¥
3.71
Sep 30
Business Description
Hubei Biocause Pharmaceutical Co Ltd
NAICS : 325998
SIC : 2899
ISIN : CNE000000F48
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.82 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 0.81 | |||||
Debt-to-EBITDA | 1.55 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.28 | |||||
Beneish M-Score | -1.32 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.2 | |||||
3-Year EBITDA Growth Rate | 79.4 | |||||
3-Year FCF Growth Rate | -24.4 | |||||
3-Year Book Growth Rate | -0.9 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.99 | |||||
9-Day RSI | 74.11 | |||||
14-Day RSI | 71.67 | |||||
6-1 Month Momentum % | -23.08 | |||||
12-1 Month Momentum % | -39.1 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.07 | |||||
Quick Ratio | 1.81 | |||||
Cash Ratio | 0.79 | |||||
Days Inventory | 74.16 | |||||
Days Sales Outstanding | 0.72 | |||||
Days Payable | 8.7 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 3.2 | |||||
Shareholder Yield % | 28.23 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 40.18 | |||||
Operating Margin % | 23.47 | |||||
Net Margin % | -1.83 | |||||
FCF Margin % | -52.33 | |||||
ROE % | -4.02 | |||||
ROA % | -0.28 | |||||
ROIC % | 3.22 | |||||
3-Year ROIIC % | 19.04 | |||||
ROC (Joel Greenblatt) % | 407.29 | |||||
ROCE % | 3.9 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio without NRI | 39.47 | |||||
Shiller PE Ratio | 21.82 | |||||
PEG Ratio | 2.99 | |||||
PS Ratio | 0.4 | |||||
PB Ratio | 0.9 | |||||
Price-to-Tangible-Book | 1.31 | |||||
EV-to-EBIT | 1.85 | |||||
EV-to-EBITDA | 1.85 | |||||
EV-to-Revenue | 0.43 | |||||
EV-to-FCF | -0.83 | |||||
Price-to-Projected-FCF | 0.13 | |||||
Price-to-Median-PS-Value | 0.63 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.58 | |||||
Price-to-Graham-Number | 1.51 | |||||
Earnings Yield (Greenblatt) % | 54.05 | |||||
FCF Yield % | -129.41 | |||||
Forward Rate of Return (Yacktman) % | 67.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Hubei Biocause Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 45,324.491 | ||
EPS (TTM) (Â¥) | -0.166 | ||
Beta | 1.2 | ||
Volatility % | 102.2 | ||
14-Day RSI | 71.67 | ||
14-Day ATR (Â¥) | 0.290353 | ||
20-Day SMA (Â¥) | 2.7605 | ||
12-1 Month Momentum % | -39.1 | ||
52-Week Range (Â¥) | 1.61 - 3.71 | ||
Shares Outstanding (Mil) | 4,940.63 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hubei Biocause Pharmaceutical Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Hubei Biocause Pharmaceutical Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Hubei Biocause Pharmaceutical Co Ltd Frequently Asked Questions
What is Hubei Biocause Pharmaceutical Co Ltd(SZSE:000627)'s stock price today?
When is next earnings date of Hubei Biocause Pharmaceutical Co Ltd(SZSE:000627)?
Does Hubei Biocause Pharmaceutical Co Ltd(SZSE:000627) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |